First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

CRS Group Infusion & injection

Our partner Atrogi announces first patient treated with its ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes – a milestone!

For more information, click here.